In our review, the adverse outcomes of AG NPP709 had been delicate and rare. Additionally, this analyze confirmed lengthy-term (twelve months) protection of AG NPP709 for the first time; within a previous phase III analyze, AG NPP709 was given only for five times.The goal of this stage II analyze was to check the safety and efficacy of CKD-497, a c